Journal Article

Leflunomide with low-dose everolimus for treatment of Kaposi’s sarcoma in a renal allograft recipient

Gopal Basu, Anjali Mohapatra, Marie Therese Manipadam, Sunithi Elizabeth Mani and George Tharayil John

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 26, issue 10, pages 3412-3415
Published in print October 2011 | ISSN: 0931-0509
Published online July 2011 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfr416
Leflunomide with low-dose everolimus for treatment of Kaposi’s sarcoma in a renal allograft recipient

Show Summary Details

Preview

Current treatment of Kaposi’s sarcoma is reduction of immunosuppression with or without addition of mammalian target of rapamycin inhibitors (mTORi). Akt signalling plays a central role in oncogenesis of Kaposi’s sarcoma. We describe a case of multifocal Kaposi’s sarcoma in a renal allograft recipient, which showed unsatisfactory early response to immunosuppression reduction along with everolimus therapy but completely resolved after adding leflunomide. mTORi impair Kaposi’s sarcoma oncogenesis by inhibiting mTOR downstream from the Akt signalling. Leflunomide inhibits Akt phosphorylation. This synergistic effect may be beneficial in treatment of Kaposi sarcoma and needs to be explored in trials.

Keywords: Akt signalling; everolimus; Kaposi’s sarcoma; leflunomide; renal transplantation

Journal Article.  1316 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.